Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
Open Access
- 1 May 2013
- journal article
- review article
- Published by Informa UK Limited in OncoTargets and Therapy
- Vol. 6, 531-538
- https://doi.org/10.2147/ott.s34498
Abstract
Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti-myeloma agents. Pomalidomide is an IMiD, structurally related to thalidomide, with enhanced antiangiogenic, antineoplastic, and anti-inflammatory properties and exhibiting potent anti-myeloma activity in vitro and in vivo. Pomalidomide has shown remarkable activity in patients who were refractory to both bortezomib and lenalidomide in Phase II and III studies. This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma.Keywords
This publication has 97 references indexed in Scilit:
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administrationCancer Chemotherapy and Pharmacology, 2012
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia, 2010
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsMicrovascular Research, 2008
- VE-cadherin is a critical endothelial regulator of TGF-β signallingThe EMBO Journal, 2008
- Transcellular Diapedesis Is Initiated by Invasive PodosomesImmunity, 2007
- Re-solving the Cadherin-Catenin-Actin ConundrumJournal of Biological Chemistry, 2006
- Dengue‐virus‐infected dendritic cells trigger vascular leakage through metalloproteinase overproductionEMBO Reports, 2006
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998